Broad Group of Stakeholders Highlight the Implications of a World Without Rebates for the Commercial Market and Patients
WASHINGTON, D.C.— On March 21st, Drug Channels Institute and Nephron Research hosted industry experts, health care leaders, and policymakers at the Operationalizing a World Without Rebates forum. The discussion focused on the Department of Health and Human Services’ (HHS) efforts to transform the existing pharmaceutical rebate price system and featured John O’Brien, Senior Advisor to the Secretary for Drug Pricing Reform at HHS, as the keynote speaker.
“Today’s forum provided critical insight into what a world without rebates could look like and the potential implications it could have for not only the health care industry, but also policymakers,” commented Adam J. Fein, CEO of Drug Channels Institute.
O’Brien noted a world without rebates requires engagement from all stakeholders in the health care system to help make it work for patients.
Eric Percher, Senior Research Analyst at Nephron Research added, “It’s important — whether you’re a manufacturer, pharmacy benefit manager, distributor, or beneficiary — to understand the impact this measure could have for Medicare and the commercial market. One thing all stakeholders must consider is the timing of the new rule, given its proposed effective date is January 1, 2020.”
While HHS continues implementation of the rule, stakeholders continue to examine its implications for the existing pharmaceutical rebate price system.
Nephron Research: At Nephron, our mission is to be essential to our clients’ investment and planning processes via the production of insightful healthcare research, impactful macro and company-specific economic analyses, and innovative events. Founded in 2017, Nephron Analysts Josh Raskin (Managed Care & Facilities) and Eric Percher (Pharma Supply Chain, Pricing, Policy & HCIT), together leverage decades of healthcare experience, unmatched perspective, and their deep industry networks to drive thematic conversations on the future of the healthcare industry. Grounded in fundamental research, Nephron’s process employs novel data partnerships and innovative approaches to existing data sets to deliver superior analytical insights for its clients.
Drug Channels Institute, a division of Pembroke Consulting, Inc., is a leading provider of specialized management education and online learning for and about the pharmaceutical industry. To access Dr. Adam Fein’s popular Drug Channels blog, visit www.drugchannels.net.